TGTX
TG Therapeutics Inc
$
27.870
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
28.0117
Open
27.540
VWAP
27.76
Vol
2.70M
Mkt Cap
4.42B
Low
27.220
Amount
74.84M
EV/EBITDA(TTM)
51.41
Total Shares
158.67M
EV
4.42B
EV/OCF(TTM)
--
P/S(TTM)
9.92
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
187.34M
+55.01%
--
--
174.39M
+61.19%
--
--
152.95M
+82.34%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for TG Therapeutics, Inc. (TGTX) for FY2025, with the revenue forecasts being adjusted by -1.2% over the past three months. During the same period, the stock price has changed by -16.56%.
Revenue Estimates for FY2025
Revise Downward
-1.2%
In Past 3 Month
Stock Price
Go Down
-16.56%
In Past 3 Month
4 Analyst Rating
14.82% Upside
Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 32.00 USD with a low forecast of 11.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
1 Sell
Hold
14.82% Upside
Current: 27.870
Low
11.00
Averages
32.00
High
50.00
14.82% Upside
Current: 27.870
Low
11.00
Averages
32.00
High
50.00
Goldman Sachs
Corinne Johnson
Neutral
initiated
$37
2025-07-10
Reason
Goldman Sachs
Corinne Johnson
Price Target
$37
2025-07-10
initiated
Neutral
Reason
Goldman Sachs analyst Corinne Johnson initiated coverage of TG Therapeutics with a Neutral rating and $37 price target. The firm believes Briuvmi revenue growth will continue to be the key driver of the shares.
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$55
2025-03-04
Reason
HC Wainwright & Co.
Edward White
Price Target
$55
2025-03-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$55
2025-01-15
Reason
HC Wainwright & Co.
Edward White
Price Target
$55
2025-01-15
Reiterates
Strong Buy
Reason
JP Morgan
Eric Joseph
Buy
Maintains
$30 → $43
2024-11-25
Reason
JP Morgan
Eric Joseph
Price Target
$30 → $43
2024-11-25
Maintains
Buy
Reason
JPMorgan raised the firm's price target on TG Therapeutics to $43 from $30 and keeps an Overweight rating on the shares. The firm says that with a potential SC Briumvi formulation coming into view beginning in the first half of 2025, it updated TG's model to reflect risk adjusted Briumvi forecasts within the at-home/self-administered anti-CD20 segment of relapsing multiple sclerosis. At $3.5B, the analyst's peak Briumvi SC forecast assumes market entry beginning in 2028 and ultimately garnering 35% share of the self-administered CD20 segment. JPMorgan sees an increasingly attractive setup to TG shares in the mid-term.
Goldman Sachs
Corinne Jenkins
Hold
Maintains
$20 → $22
2024-11-05
Reason
Goldman Sachs
Corinne Jenkins
Price Target
$20 → $22
2024-11-05
Maintains
Hold
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Maintains
$49 → $55
2024-11-05
Reason
HC Wainwright & Co.
Edward White
Price Target
$49 → $55
2024-11-05
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for TG Therapeutics Inc (TGTX.O) is 19.98, compared to its 5-year average forward P/E of 18.87. For a more detailed relative valuation and DCF analysis to assess TG Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
18.87
Current PE
19.98
Overvalued PE
86.64
Undervalued PE
-48.91
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-11.79
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
74.77
Undervalued EV/EBITDA
-98.35
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
103.38
Current PS
0.00
Overvalued PS
304.41
Undervalued PS
-97.65
Financials
Annual
Quarterly
FY2025Q2
YoY :
+92.13%
141.15M
Total Revenue
FY2025Q2
YoY :
+295.22%
34.84M
Operating Profit
FY2025Q2
YoY :
+309.75%
28.19M
Net Income after Tax
FY2025Q2
YoY :
+325.00%
0.17
EPS - Diluted
FY2025Q2
YoY :
+33.56%
7.39M
Free Cash Flow
FY2025Q2
YoY :
-2.39%
86.58
Gross Profit Margin - %
FY2025Q2
YoY :
-166.72%
-13.05
FCF Margin - %
FY2025Q2
YoY :
+113.35%
19.97
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
369.4K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
629.4K
USD
2
0-12
Months
1.4M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
134.7K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
165.5K
Volume
Months
6-9
2
296.7K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
369.4K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
629.4K
USD
2
0-12
Months
1.4M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TGTX News & Events
Events Timeline
2025-08-04 (ET)
2025-08-04
12:02:42
TG Therapeutics falls -14.1%
2025-08-04
11:03:34
Video: Why These Stocks Are Moving Today
2025-08-04
10:00:26
TG Therapeutics falls -16.5%
Sign Up For More Events
Sign Up For More Events
News
8.5
08-08SeekingAlphaTG Therapeutics files automatic mixed securities shelf
4.5
08-04BenzingaCrude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results
9.5
08-04BenzingaBriumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide
Sign Up For More News
People Also Watch
BEPC
Brookfield Renewable Corp
33.780
USD
+1.14%
BRZE
Braze Inc
25.300
USD
+4.94%
PLXS
Plexus Corp
135.740
USD
+2.01%
ALGM
Allegro Microsystems Inc
31.860
USD
-0.09%
KRC
Kilroy Realty Corp
38.730
USD
+2.19%
MSM
MSC Industrial Direct Co Inc
88.830
USD
+2.82%
PRIM
Primoris Services Corp
113.410
USD
-1.03%
GDS
GDS Holdings Ltd
33.920
USD
-6.58%
MATX
Matson Inc
109.910
USD
+1.72%
AEIS
Advanced Energy Industries Inc
162.520
USD
+2.34%
FAQ
What is TG Therapeutics Inc (TGTX) stock price today?
The current price of TGTX is 27.87 USD — it has increased 2.77 % in the last trading day.
What is TG Therapeutics Inc (TGTX)'s business?
What is the price predicton of TGTX Stock?
What is TG Therapeutics Inc (TGTX)'s revenue for the last quarter?
What is TG Therapeutics Inc (TGTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for TG Therapeutics Inc (TGTX)'s fundamentals?
How many employees does TG Therapeutics Inc (TGTX). have?